Hypo or HyperthyroidismQThy2Dvc3DNCT07610460
Thyroid Uptake Quantification Validation on a Three-dimensional (3D) Cadmium-Zinc-Telluride (CZT) New Generation Gamma Camera
An observational study of Hypo or Hyperthyroidism, run by Centre Hospitalier Princesse Grace at 1 site in Monaco.
Trial summary
Thyroid scintigraphy using technetium-99m (99mTc) pertechnetate is traditionally performed using planar imaging to estimate thyroid uptake. Recent developments in quantitative SPECT/CT allow direct activity quantification from three-dimensional tomographic acquisitions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypo or Hyperthyroidism
- How many people
- 27 participants
- Where
- 1 siteMonaco
- Study dates
- 1 Oct 2025to 31 Mar 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: No selection it's 27 consecutive patients
Who may be able to join
- hypothyroidism
- hyperthyroidism
Who cannot join
- Pregnant women
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Clinical Evaluation of Thyroid Uptake Quantification With Technetium-99m (99mTc)-Pertechnetate: Comparison Between Gold Standard Planar and Quantitative 3D CZT Single Photon Emission Computed Tomography/Cumputed Tomography (SPECT/CT) Scintigraphy
Thyroid scintigraphy using technetium-99m (99mTc) pertechnetate is traditionally performed using planar imaging to estimate thyroid uptake. Recent developments in quantitative SPECT/CT allow direct activity quantification from three-dimensional tomographic acquisitions. The aim of this study was to evaluate the accuracy of thyroid uptake quantification obtained from 3D SPECT/CT compared with conventional planar image.
Read the detailed description
Planar and SPECT/CT scintigraphy will be performed on a new generation 3D CZT gamma camera and thyroid uptake (TU) value will be calculated on planar acquisition for 27 consecutive patients referred in the department of the investigators for hyper or hypothyroidism.
With a quantitative approach using attenuation, scatter correction and iterative algorithm (12 iterations and 8 subsets) with post filter Median Full Width at Half Maximum (FWHM=3), the TU value with SPECT or SPECT/CT acquisitions can be calculate.
The objective will be to evaluate the potential of a new 3D CZT gamma camera to estimate the thyroid uptake on SPECT (Tomography without attenuation correction) and SPECT/CT (tomography with attenuation correction) acquisitions compared with standard planar scintigraphy as a gold standard.
To established this study it will be necessary to introduce cross-calibration factors performed from homogeneous phantoms, for planar and 3D SPECT acquisitions, to estimate the thyroid uptake values.
- Conditions
- Hypo or Hyperthyroidism
- Being tested
- No Intervention: Observational Cohort
- Keywords
- thyroid, uptake, quantification, CZT, Planar, 3D gamma camera, SPECT/CT
- Medical subject headings
- Hyperthyroidism, Thyroid Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No Intervention: Observational CohortOther
Planar and SPECT/CT acquisitions
What is being measured
The primary outcome is the main question the study is designed to answer.
Quantification of thyroid uptake on a 3D CZT gamma camera
Measured: Day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 May 2026
- Study start1 Oct 2025
- Primary completion31 Mar 2026
- Study completion31 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Hypo or HyperthyroidismStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Princesse Grace
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07610460
- Sponsor's protocol ID
- 26-05
- Acronym
- QThy2Dvc3D
- Status last verified
- May 2026
- First submitted
- 15 May 2026
- Last updated
- 28 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Serrano B, Amblard R, Beaumont T, Hugonnet F, Dietz M, Berthier F, Garnier N, Villeneuve R, Nataf V, Mocquot F, Montemagno C, Faraggi M, Paulmier B. Quantitative analysis of 99mTc-pertechnetate thyroid uptake with a large-field CZT gamma camera: feasibility and comparison between SPECT/CT and planar acquisitions. EJNMMI Phys. 2023 Jul 31;10(1):45. doi: 10.1186/s40658-023-00566-3.
PubMed 37522931Mariani G, Tonacchera M, Grosso M, Orsolini F, Vitti P, Strauss HW. The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism. J Nucl Med. 2021 Mar;62(3):304-312. doi: 10.2967/jnumed.120.243170. Epub 2020 Oct 2.
PubMed 33008929Giovanella L, Avram AM, Iakovou I, Kwak J, Lawson SA, Lulaj E, Luster M, Piccardo A, Schmidt M, Tulchinsky M, Verburg FA, Wolin E. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2514-2525. doi: 10.1007/s00259-019-04472-8. Epub 2019 Aug 7.
PubMed 31392371Gnesin S, Leite Ferreira P, Malterre J, Laub P, Prior JO, Verdun FR. Phantom Validation of Tc-99m Absolute Quantification in a SPECT/CT Commercial Device. Comput Math Methods Med. 2016;2016:4360371. doi: 10.1155/2016/4360371. Epub 2016 Dec 14.
PubMed 28096891Ritt P, Vija H, Hornegger J, Kuwert T. Absolute quantification in SPECT. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S69-77. doi: 10.1007/s00259-011-1770-8. Epub 2011 Apr 12.
PubMed 21484383
Study at a glance
From the registry record, last updated by the sponsor on 28 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Evaluation of Thyroid Uptake Quantification With Technetium-99m (99mTc)-Pertechnetate: Comparison Between Gold Standard Planar and Quantitative 3D CZT Single Photon Emission Computed Tomography/Cumputed Tomography (SPECT/CT) Scintigraphy
- ClinicalTrials.gov ID
- NCT07610460
- Acronym / sponsor ID
- QThy2Dvc3D / 26-05
- Conditions
- Hypo or Hyperthyroidism
- Keywords
- thyroid, uptake, quantification, CZT, Planar, 3D gamma camera, SPECT/CT
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 27 participants (actual)
- Lead sponsor
- Centre Hospitalier Princesse GraceUniversity, hospital or other
- Study start
- 1 Oct 2025 (actual)
- Primary completion
- 31 Mar 2026 (actual)
- Study completion
- 31 Mar 2026 (actual)
- First posted
- 28 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Thyroid scintigraphy using technetium-99m (99mTc) pertechnetate is traditionally performed using planar imaging to estimate thyroid uptake. Recent developments in quantitative SPECT/CT allow direct activity quantification from three-dimensional tomographic acquisitions. The aim of this study was to evaluate the accuracy of thyroid uptake quantification obtained from 3D SPECT/CT compared with conventional planar image.
Detailed description
Planar and SPECT/CT scintigraphy will be performed on a new generation 3D CZT gamma camera and thyroid uptake (TU) value will be calculated on planar acquisition for 27 consecutive patients referred in the department of the investigators for hyper or hypothyroidism.
With a quantitative approach using attenuation, scatter correction and iterative algorithm (12 iterations and 8 subsets) with post filter Median Full Width at Half Maximum (FWHM=3), the TU value with SPECT or SPECT/CT acquisitions can be calculate.
The objective will be to evaluate the potential of a new 3D CZT gamma camera to estimate the thyroid uptake on SPECT (Tomography without attenuation correction) and SPECT/CT (tomography with attenuation correction) acquisitions compared with standard planar scintigraphy as a gold standard.
To established this study it will be necessary to introduce cross-calibration factors performed from homogeneous phantoms, for planar and 3D SPECT acquisitions, to estimate the thyroid uptake values.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- No selection it's 27 consecutive patients
Key inclusion criteria (2 listed)
- hypothyroidism
- hyperthyroidism
Key exclusion criteria (1 listed)
- Pregnant women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No Intervention: Observational CohortPlanar and SPECT/CT acquisitions | Other | – |
Primary outcome
Quantification of thyroid uptake on a 3D CZT gamma camera
Time frame: Day 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 May 2026.
- Background: PubMed 37522931Serrano B, Amblard R, Beaumont T, Hugonnet F, Dietz M, Berthier F, Garnier N, Villeneuve R, Nataf V, Mocquot F, Montemagno C, Faraggi M, Paulmier B. Quantitative analysis of 99mTc-pertechnetate thyroid uptake with a large-field CZT gamma camera: feasibility and comparison between SPECT/CT and planar acquisitions. EJNMMI Phys. 2023 Jul 31;10(1):45. doi: 10.1186/s40658-023-00566-3.
- Background: PubMed 33008929Mariani G, Tonacchera M, Grosso M, Orsolini F, Vitti P, Strauss HW. The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism. J Nucl Med. 2021 Mar;62(3):304-312. doi: 10.2967/jnumed.120.243170. Epub 2020 Oct 2.
- Background: PubMed 31392371Giovanella L, Avram AM, Iakovou I, Kwak J, Lawson SA, Lulaj E, Luster M, Piccardo A, Schmidt M, Tulchinsky M, Verburg FA, Wolin E. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2514-2525. doi: 10.1007/s00259-019-04472-8. Epub 2019 Aug 7.
- Background: PubMed 28096891Gnesin S, Leite Ferreira P, Malterre J, Laub P, Prior JO, Verdun FR. Phantom Validation of Tc-99m Absolute Quantification in a SPECT/CT Commercial Device. Comput Math Methods Med. 2016;2016:4360371. doi: 10.1155/2016/4360371. Epub 2016 Dec 14.
- Background: PubMed 21484383Ritt P, Vija H, Hornegger J, Kuwert T. Absolute quantification in SPECT. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S69-77. doi: 10.1007/s00259-011-1770-8. Epub 2011 Apr 12.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hypo or Hyperthyroidism, run by Centre Hospitalier Princesse Grace at 1 site in Monaco.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Monaco. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quantification of thyroid uptake on a 3D CZT gamma camera (time frame: Day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07610460, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 May 2026.